@article{10.4137/BCBCR.S30771, author={Yan Song and Yanni Hao and Alexander R. Macalalad and Peggy L. Lin and James E. Signorovitch and Eric Q. Wu}, journal={Breast Cancer: Basic and Clinical Research}, publisher={Libertas Academica}, title={Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer}, year={2015}, month={09}, volume={9}, url={www.la-press.com/clinical-outcomes-with-first-line-endocrine-therapy-or-chemotherapy-in-article-a5049}, pages={67--72}, abstract={ Objective: To describe patient profiles and clinical outcomes associated with first-line endocrine monotherapy (ET) and chemotherapy (CT) for postmenopausal HR+/HER2- metastatic breast cancer (mBC) patients. Methods: This is a retrospective chart review of 139 postmenopausal HR+/HER2- mBC patients initiating first-line ET monotherapy or CT. Overall survival (OS) was described using Kaplan–Meier curves. Exploratory comparative proportional hazards regression was conducted. Results: Patients on first-line CT had significantly more frequent liver metastases than patients on first-line ET monotherapy at baseline. The median OS was 35.5 months [95% confidence interval (CI), 22.7–41.2 months] for patients on first-line ET monotherapy and 22.2 months (95% CI, 13.6–25.9 months) for those on first-line CT (P = 0.021). Adjusting for baseline characteristics, the OS between first-line ET monotherapy and CT was not significantly different. Conclusions: Patients who were prescribed CT as first-line treatment had evidence of more advanced disease at baseline and shorter OS than those who received ET monotherapy as first-line treatment, suggesting a need for additional safe and effective treatment options for these patients. }, doi={10.4137/BCBCR.S30771}, }